October 2023 in “Dermatology practical & conceptual” This study observed that among 120 patients recovering from COVID-19, severe diffuse hair loss typically began less than two months post-infection, with the majority of patients experiencing a severe degree of hair loss and positive hair pull tests, often alongside vitamin D deficiency.
1 citations
,
October 2022 in “Cureus” This study reported that over half of recovered COVID-19 patients in Saudi Arabia experienced hair loss, with factors such as high fever, female gender, and prior hair loss significantly associated with incidence of acute telogen effluvium.
2 citations
,
September 2022 in “Cureus” In this study conducted in the Makkah region, researchers observed that hair loss, mostly telogen effluvium, is a prevalent post-COVID-19 symptom, particularly among women and those with multiple health issues.
3 citations
,
April 2022 in “Clinical, Cosmetic and Investigational Dermatology” This review discusses evidence-based complementary strategies for enhancing hair regrowth after post-COVID-19 telogen effluvium and reports no new clinical results.
8 citations
,
February 2022 in “Journal of Clinical Medicine” This study found that a notable percentage of COVID-19 patients experienced post-infection telogen effluvium, although no significant associations with infection-related factors were identified.
25 citations
,
December 2021 in “Journal of Medical Virology” This systematic review reports that acute telogen effluvium may occur as a stress-induced hair loss following COVID-19 recovery, with most patients experiencing hair regrowth over time.
7 citations
,
September 2021 in “Anais Brasileiros De Dermatologia” This study found that in patients with telogen effluvium after recovering from COVID-19, earlier alopecia onset was associated with younger age, female gender, hypothyroidism, and more severe coronavirus infections.
25 citations
,
August 2021 in “Irish Journal of Medical Science (1971 -)” This study found that COVID-19 infection is a frequent cause of acute telogen effluvium, leading to excessive hair loss within 2–3 months after infection.
39 citations
,
August 2021 in “JAAD International” This study found that telogen effluvium and trichodynia are common in patients after COVID-19, and their severity may be influenced by the severity of the COVID-19 infection.
32 citations
,
July 2021 in “Journal of The American Academy of Dermatology” This study found that acute telogen effluvium after COVID-19 typically began about 1.5 months post-infection and resolved sooner than typical cases, with most resolving in under two months.
56 citations
,
May 2021 in “Journal of infection/The Journal of infection” This study found that 80% of hospitalized COVID-19 survivors experienced at least one post-COVID symptom seven months after discharge, with fatigue, hair loss, and dyspnea being the most common.
1 citations
,
May 2021 in “InterConf” This publication discusses the potential mechanisms behind telogen alopecia as a dermatological manifestation of post-COVID-19 syndrome and reports no new clinical results.
44 citations
,
January 2021 in “Dermatologic Therapy” This study suggests that COVID-19 infection may trigger telogen effluvium, a condition of hair shedding, though medication side effects and pandemic-related stress cannot be excluded as contributing factors.
27 citations
,
December 2020 in “Experimental Dermatology” This study reported that COVID-19 was causally associated with postinfectious hair shedding, which varied with disease severity, but hair completely recovered.
58 citations
,
November 2020 in “International Journal of Dermatology” COVID-19 may cause a temporary hair loss condition called telogen effluvium in some patients after recovery.
51 citations
,
November 2020 in “Journal of the European Academy of Dermatology and Venereology” This article discusses SARS-CoV-2-induced telogen effluvium in a multicentric study and reports no new clinical results.
737 citations
,
August 2020 in “Journal of Infection” This study found that most patients hospitalized for COVID-19 experienced persistent symptoms over 100 days post-admission, with no significant difference in symptoms between those treated in regular wards and intensive care units.
43 citations
,
July 2020 in “Dermatologic Therapy” This study observed a significant increase in certain dermatologic conditions a month and two months after the onset of the COVID-19 pandemic in Turkey, which may suggest a link with asymptomatic COVID-19 infection.
39 citations
,
June 2020 in “Dermatologic Therapy” In this study, individuals reported a decrease in dermatologist visits for hair and scalp conditions like telogen effluvium and alopecia areata during COVID-19 quarantine, despite increased occurrences.
31 citations
,
May 2020 in “Dermatologic Therapy” Quarantine stress likely worsened hair loss in women, but video consultations helped manage their condition and reduce anxiety.
36 citations
,
May 2020 in “Journal of the European Academy of Dermatology and Venereology” Dermatologists should watch for skin symptoms in COVID-19 patients, prioritize urgent cases, and use telemedicine.
56 citations
,
August 2019 in “Clinical, Cosmetic and Investigational Dermatology” This essay discusses telogen effluvium, the issues surrounding its diagnosis and differentiation from other forms of hair loss, and emphasizes the need for empathetic patient care; it reports no new clinical findings.
13 citations
,
May 2017 in “Dermatologica Sinica” In this study, researchers characterized telogen effluvium observed in 14 patients following a dengue outbreak in Tainan, noting a mean onset time of 2.1 months post-infection.
